Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809253 | 0.95 | MAPT (0.59) | MAPTRAB9ANPC1RECQLKDM4E | |
| SCHEMBL89656 | 0.92 | RAB9A (0.50) | MAPTRAB9ANPC1RECQLKDM4E | |
| SCHEMBL89596 | 0.92 | RAB9A (0.50) | MAPTRAB9ANPC1RECQLKDM4E | |
| SCHEMBL38987 | 0.91 | MAPT (0.59) | MAPTRAB9AKDM4EGAACA1 | |
| SCHEMBL12733610 | 0.90 | MAPT (0.54) | MAPTRAB9ANPC1RECQLKDM4E | |
| SCHEMBL14811909 | 0.87 | MAPT (0.50) | MAPTRAB9ANPC1RECQLKDM4E | |
| SCHEMBL3490269 | 0.86 | MAPT (0.53) | MAPTRAB9ANPC1RECQLKDM4E | |
| SCHEMBL9071285 | 0.86 | SMPD1 (0.56) | MAPTRAB9ANPC1KDM4ECA1 | |
| SCHEMBL38560 | 0.86 | MAPT (0.54) | MAPTRAB9ANPC1RECQLKDM4E | |
| SCHEMBL10268140 | 0.85 | PLA2G2A (0.55) | MAPTRAB9ANPC1RECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292110-B1 | N-PIPERIDIN-4-YL DERIVATIVES | MERCK SHARP & DOHME (NL) | 2019-08-21 | — | — | EP | disclosed |
| EP-3292110-A1 | N-PIPERIDIN-4-YL DERIVATIVES | Merck Sharp & Dohme B.V. (NL) | 2018-03-14 | — | — | EP | disclosed |
| US-8993757-B2 | N-piperidin-4-yl derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-03-31 | — | — | US | disclosed |
| US-20140329822-A1 | N-PIPERIDIN-4-YL DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2014-11-06 | — | — | US | disclosed |
| WO-2013041457-A1 | N-PIPERIDIN-4-YL DERIVATIVES | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006074924-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | MAPT 1266/4885RAB9A 639/4885NPC1 3663/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | MAPT 1089/4885RAB9A 500/4885NPC1 2676/4885 |
| US-20140329822-A1 | N-PIPERIDIN-4-YL DERIVATIVES | PGR, CYP19A1, BRCA1 | MAPT 4046/4885RAB9A 1611/4885NPC1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.